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Summary A case-control study was conducted to determine whether the development of leukaemia was
associated with chemotherapy for neoplasms of the ovary or breast, in a population where most such
chemotherapy consisted of cyclophosphamide alone. Cases and controls were identified from the National
Cancer Registry of the German Democratic Republic. Cases were women who had developed leukaemia as a
second primary after an initial diagnosis, at least one year before, of an ovarian or breast tumour. Controls
were patients with an ovarian tumour or breast cancer who had survived to the year when the case developed
a leukaemia but who had not themselves developed a second malignancy. Controls were matched to cases by
the site of the first primary and its year of diagnosis, as well as year of birth. The relative risk for acute
leukaemia following treatment with cyclophosphamide alone was significantly elevated (P<0.05), at 14.6 for
ovarian tumour patients and 2.7 for breast cancer patients. Among breast cancer patients the increased risk of
leukaemia associated with chemotherapy was confined to women who had been under 50 years of age at the
time of diagnosis of the breast cancer (for whom the relative risk was 13.1). No excess risk of leukaemia was
observed in association with radiotherapy for either ovarian or breast cancer patients. The present findings
strongly suggest that cyclophosphamide as a single chemotherapeutic agent is capable of inducing leukaemia
in humans.
Cyclophosphamide is carcinogenic by several routes of
administration in rats and mice (Schmahl & Habs, 1979;
IARC, 1981). In humans there is also strong evidence that it
is a carcinogen (Plotz et al., 1979; Elliot et al., 1982),
producing tumours of the bladder and possibly other sites.
There are a number of case reports of acute leukaemia
following treatment with cyclophosphamide of non-
malignant diseases including rheumatoid arthritis, Wegener's
granulomatosis, chronic glomerulonephritis, idiopathic
thrombocytopaenia purpura, and Sj6gren's syndrome
(Grunwald & Rosner, 1979). While cyclophosphamide is
suspected to be a leukaemogen, it is widely believed to be
less potent than many other nitrogen mustard-derived
alkylating agents, and it is recommended as a component of
adjuvant therapy following surgery for breast cancer
(National Institutes of Health, 1986).
Studies of leukaemia in cancer patients treated with cyclo-
phosphamide have been difficult to interpret, because it is
often given in combination with other agents known to be
leukaemogenic. Although an increase in the risk of acute
non-lymphocytic leukaemia (ANLL) following Hodgkin's
disease has been appreciated for some time (Brody et al.,
1977) it has not been possible to implicate directly cyclo-
phosphamide, even though it has been widely used in
Hodgkin's disease therapy (Boivin & Hutchison, 1984).
Acute leukaemia also occurs in excess in patients with non-
Hodgkin's lymphoma who have undergone chemotherapy
including cyclophosphamide (Pedersen-Bjergaard et al.,
1985). In a study of multiple myeloma patients, there were
no cases of ANLL among 14 5-year survivors who had been
treated with cyclophosphamide alone (Buckman et al., 1982).
In a recent report, however, there were 3 cases of ANLL or
preleukaemia among 298 ovarian cancer patients who
received only cyclophosphamide, as compared with 2 cases
out of 1286 women who received no chemotherapy, a
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difference which was statistically significant at the 0.01 level
(Greene et al., 1986).
Ovarian cancer patients have a clear and substantial
increase in risk of developing acute leukaemia following
treatment with other alkylating agents (Reimer et al., 1977;
Greene et al., 1982), including melphalan (Einhorn, 1978;
Einhorn et al., 1982) and treosulfan (Pedersen-Bjergaard et
al., 1980).
In the present study we examine the role of cytotoxic
therapy in the occurrence of leukaemia following treatment
for breast and ovarian cancer in the German Democratic
Republic (GDR). In the time period under investigation
cyclophosphamide was a very widely used cytotoxic agent in
the GDR and was frequently used alone. Therefore the
results should be particularly informative with regard to the
question of this drug's leukaemogenicity in humans.
Methods
Cancer case reporting is obligatory in the GDR. All
physicians are required to report every cancer case to the
National Cancer Registry (NCR) via the Cancer Control
Agencies which are located in each of the 227 counties of the
GDR. It is estimated that almost all cancer cases are
reported by this mechanism, although an exact figure is not
available.
Identification ofcases
The study was based on the records of the NCR, which is
organised on a tumour, rather than a person, basis, so that
each new primary diagnosis is assigned a new registration
number, even if it occurs in the same individual (Waterhouse
et al., 1982). However, each registration states whether the
cancer is the first, second or later primary malignancy in the
individual. The starting point of this study was the set of all
leukaemias recorded as the second primary malignancy. To
determine the site and year of the first primary, the following
approaches were used in parallel. For the years 1968-1980
computerised files were available and these were searched to
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identify a tumour occurring in a person of the same sex,
birth date and name as the leukaemia case. At the same time
the original leukaemia case reports were obtained from the
registry's archives. The report should contain the site and
year of the previous neoplasm. Where the information was
inadequate, further information was sought through the local
county Cancer Control Agency. Ultimately a group of cases
was identified who had a breast or ovarian neoplasm after
1960 and who developed a leukaemia at least one year later,
and before the end of 1980.
Classification of tumours
The NCR uses a detailed internal tumour classification and
coding system which can be translated into the 7th through
9th Revisions of the International Classification of Disease.
The ICD-O morphology code has been systematically used
in the NCR for cases registered from 1976 and thereafter. In
the present study, the NCR case report and the hospital
records were used to reclassify all solid tumours and
leukaemias according to the ICD-O. Because the NCR
accepts papillary cystadenomas of non-malignant or
borderline histology as ovarian tumours, these were not
excluded from either case or control groups in the initial
study design.
Selection ofcontrols
For each leukaemia occurring as a second primary, matched
controls were selected. The matching was by first cancer site,
the calendar year of its occurrence, and year of birth. For
cases following breast cancer, the controls were required to
be born in the same calendar year as the case; for ovarian
tumour cases, controls had to have been born within two
calendar years of the case. In addition, a control had to be
alive with no reportable second primary tumour (other than
basal cell carcinoma) up to the year in which the case
developed the leukaemia.
For cases whose first tumours occurred between 1968 and
1980, potential controls could be identified from
computerised files. A manual search was, however, necessary
for the years 1960-1967. Using these two approaches it was
possible to identify all potential controls who satisfied the
matching criteria of year of birth, first tumour site and year
of its occurrence.
It was then necessary to ascertain whether a potential
control had survived to the time at which the case had
developed a second tumour, and whether she had developed
a second primary up to that time.
Complete survival information is not maintained by the
NCR, and a second primary cancer in a potential control
could only be identified by the NCR if it had occurred after
1968. The missing information on survival and second
primaries in potential controls was therefore requested from
the Cancer Control Agencies, who maintain patient-based
records including an obligatory five-year follow-up. In some
cases, where the five-year period was over, it was necessary
to make direct inquiries of the potential control, her family
or her physician. Since the number of potential controls was
sometimes very large (up to 300), a maximum of ten
potential controls were randomly selected for each case, to
reduce the burden on the local agencies.
From the potential controls who met the matching
criteria, two final controls were randomly selected for each
leukaemia following breast cancer, and four for each
leukaemia following an ovarian tumour. If fewer than the
required number of final controls were found, an additional
ten potential controls were randomly selected and the
process repeated, although this was seldom necessary.
For one patient born in 1885 who developed a breast
cancer in 1967 and chronic lymphatic leukaemia in 1978,
only one control could be found. This patient and her
control were subsequently dropped. Both women had
undergone radiotherapy; neither one had received
chemotherapy.
Treatment information
Individual treatment information for the first cancer was
compiled from NCR files, and from hospital charts which
were requested for each study subject. The latter were
available for 76.6% of ovarian tumours and 79.5% of breast
cancer cases and controls, and there was no statistical
difference in the proportion of cases and controls for whom
charts were received.
For a few cases, more precise pathological information
was present in the hospital charts than in the corresponding
NCR record. Hospital records generally contained more
complete information on chemotherapy than did the NCR
files, particularly with regard to the dose administered. There
was no mention of chemotherapy in the NCR record of 24
out of 77 ovarian cancer and breast cancer cases for whom
the hospital chart reported chemotherapy. The situation with
respect to radiotherapy was rather different. The NCR had
recorded radiotherapy in all but one of the 189 instances in
which it was recorded in available hospital records. In an
additional 11 instances the NCR had information on radio-
therapy which was not noted in the hospital record, due to
the reporting of radiation treatment direct to the NCR from
the regional radiotherapy centres. In compiling the treatment
histories, the more complete of the two data sources was
used in each case.
Patients were classified as having received chemotherapy if
any mention of treatment with a non-hormonal, anti-cancer
drug was found in the hospital chart or in the NCR records.
Similarly, patients were classified as having received radio-
therapy or hormonal therapy if this was mentioned in the
patient's chart or in NCR records. Only treatments prior to
the time when the case developed the leukaemia were
considered.
Statistical methods
The data were analysed using standard methods for matched
case-control studies (Breslow & Day, 1980).
Results
A more detailed presentation of the basic data is available in
Mehnert et al. (1986).
There were 93 leukaemias recorded following breast cancer
and 12 following ovarian tumours. Of these, 52 and 9 were
acute leukaemias respectively. Table I gives the number of
cases by leukaemia sub-types and the average interval
between the first and second primary tumour.
There was no significant difference (P>0.05) in the mean
interval between the solid tumour and the leukaemia by site
of first primary. Leukaemia was diagnosed more than 10
Table I Leukaemia as a second primary tumour. Average number
of years between diagnosis of first cancer and leukaemia (number of
cases in brackets)
First cancer
Type ofleukaemia Ovary Breast
Acute leukaemia, not otherwise specified 6.3 (3) 8.0 (23)
Acute myeloid leukaemia 4.6 (5) 6.2 (28)
Acute Iymphoid leukaemia 2.0 (1) 11.0 (1)
Chronic myeloid leukaemiaa 6.0 (3) 5.6 (29)
Chronic lymphatic leukaemiab - (0) 6.2 (12)
Total 5.2 (12) 6.4 (93)
aIncludes one case of myeloid, not otherwise specified; bIncludes
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years after breast cancer in 17 out of 51 patients with ANLL
and in 6 out of 41 patients with non-acute leukaemias. All
leukaemias after ovarian tumours occurred within 10 years
of the first neoplasm. The interval between breast cancer and
leukaemia was not significantly different between those
patients who had received chemotherapy and those who had
not.
In the case-control analyses, three dichotomous classi-
fications of treatment were used: chemotherapy, radio-
therapy and (for breast cancer only) hormone therapy, which
included radiation-induced ovarian ablation. In addition, we
examined separately the risk associated with cyclo-
phosphamide treatment. The relative risk associated with
each type of treatment was estimated for all leukaemias,
acute leukaemia only, and non-lymphocytic leukaemia only.
Thus, each relative risk quoted below is specific for a
category of leukaemia and a type of treatment, and
compares the risk of leukaemia in patients who received the
treatment with the risk in those who did not.
Leukaemiafollowing ovarian tumours
All of the nine patients who developed acute leukaemia after
an ovarian tumour had received chemotherapy. One had
received triazaquon, a potent alkylating agent used for a
short period in the GDR, as well as cyclophosphamide, and
the rest had been treated with cyclophosphamide only.
Among the three patients with non-acute leukaemia
following an ovarian tumour, one had received cyclo-
phosphamide. One control had received triazaquon only, and
in 14 chemotherapy-treated, ovarian tumour controls the
only anti-cancer drug used was cyclophosphamide.
Table II reports the estimated relative risks and 90%
confidence intervals (used to parallel a one-sided 5% level
hypothesis test) for leukaemia following ovarian cancer, by
type of leukaemia and treatment for ovarian cancer. The
confidence intervals are rather wide because of the small
number of cases, but nonetheless exclude unity for cyclo-
phosphamide only or any chemotherapy treatment. In
contrast, there was no significant elevation of risk for any
leukaemia subtype in relation to radiotherapy.
In order to address concerns that the grade of malignancy
of the primary ovarian tumour might be inherently related to
the likelihood of developing a subsequent leukaemia (rather
than simply through the effect of therapy), the analyses were
repeated using only malignant ovarian tumours. This
resulted in the elimination of one leukaemia case (a chronic
myelogenous leukaemia) and the replacement of 14 controls
which did not have ICD-O behaviour code 3 (malignant) for
the ovarian primary. For all leukaemias occurring after any
chemotherapy, the relative risk resulting from the re-analysis
was 8.9 (90% CI: 1.4-57.4). When treatment was restricted
to cyclophosphamide only, the relative risk using only
malignant tumours of the ovary was estimated to be 3.5
(90% C.I.: 0.63-20.1). For acute leukaemia the revised
relative risk associated with cyclophosphamide only was 5.7
(90% CI: 0.60-54.1).
Leukaemiafollowing breast cancer
Single drug treatment with cyclophosphamide also pre-
dominated for the breast cancer patients. Of the 52 breast
cancer patients who developed acute leukaemia, 11 had
received chemotherapy, in each case cyclophosphamide only.
Of the 41 patients who developed chronic leukaemia after
breast cancer, five had received chemotherapy. Of these, two
had received cyclophosphamide only, one had received
triazaquon only, and two had received combined drug
schemas in which cyclophosphamide was the only alkylating
agent. Of 20 breast cancer control patients who received
cyclophosphamide, 19 were treated with cyclophosphamide
only and one was treated with a combination regime
including cyclophosphamide.
Table III reports the relative risk estimates and confidence
intervals for leukaemia following breast cancer. The relative
risk of chemotherapy and cyclophosphamide alone differed
significantly from unity for acute leukaemia, but not for
total leukaemia. The point estimates of relative risk
associated with chemotherapy were much lower than those
for leukaemia following ovarian cancer, but the confidence
intervals were much narrower due to the larger number of
cases.
All but eight of the 52 breast cancer patients who
developed acute leukaemia had undergone radiotherapy, and
of the 11 acute leukaemia cases following breast cancer who
had received chemotherapy, all but one had also undergone
radiotherapy. Eight of the 41 patients who developed chronic
leukaemias had had no radiotherapy. There was no
suggestion of increased risk of developing any kind of
leukaemia in association with radiotherapy for breast cancer.
The overall relative risk of leukaemia for radiotherapy-
treated patients was 1.0.
Similarly, patients who underwent hormone therapy for
breast cancer did not differ significantly in their risk of
developing leukaemia from those not so treated. This was
also true of patients who had undergone radiation-induced
ovarian ablation.
Further analyses revealed that the excess risk of leukaemia
following chemotherapy for breast cancer was confined to
women under 50 years of age at the time of breast cancer
diagnosis. For all leukaemias, the relative risk for chemo-
therapy was 13.1 (95% CI: 2.5-68.0) for women under 50,
whereas for those over 50 it was 0.94. This difference in risk
between women under and over 50 is unlikely to be due to
chance (X2=6.9; P<0.01).
When only acute leukaemias were considered, the esti-
.mated relative risk of leukaemia for chemotherapy was 1.1
for women over 50 and infinite for women under 50 (lower
confidence limit= 1.7). For women under 60, the relative risk
Table II Relative risk of leukaemia following ovarian tumours by type of leukaemia and treatment received
Numbers oftreated
90% patients/total
Type of Treatmentfor Relative confidence
leukaemia ovarian tumours risk intervals Cases Controls?
All Any chemotherapy 15.7 2.7-91.7 10/12 15/48
All Cyclophosphamide only 7.6 2.0-29.2 9/12 14/48
Acute Any chemotherapy oc 1.5- 9/9 12/36
Acute Cyclophosphamide only 14.6 2.4-88.7 8/9 11/36
Non-lymphatic Any chemotherapy 15.4 2.6-90.4 9/11 14/44
Non-lymphatic Cyclophosphamide only 7.4 1.9-28.7 8/11 13/44
All Radiotherapy 1.0 0.35-2.8 6/12 20/48
Acute Radiotherapy 1.1 0.32-4.0 4/9 15/36
aControls matched to the cases which fall in the indicated leukaemia category. Note that the relative risks in
the table take account of the matching, and may differ somewhat from the relative risks calculable from the
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Table III Relative risk ofleukaemia following breast cancer by type of leukaemia and treatment received
Numbers oftreated
90% patients/total
Type of Treatmentfor Relative confidence
leukaemia breast cancer risk intervals Cases Controlsa
All Any chemotherapy 1.7 0.95-3.1 16/93 20/185
All Cyclophosphamide only 1.3 0.68-2.5 13/93 19/185
Acute Any chemotherapy 2.6 1.2-5.8 11/52 10/104
Acute cyclophosphamide only 2.7 1.2-6.3 11/52 9/104
Non-lymphatic Any chemotherapy 1.3 0.69-2.3 14/80 17/160
Non-lymphatic Cyclophosphamide only 1.3 0.64-2.5 10/80 15/160
All Radiotherapy 1.00 0.56-1.8 77/93 154/185
Acute Radiotherapy 0.86 0.39-1.8 44/52 90/104
All Hormonal 1.5 0.94-2.4 34/93 53/185
Acute Hormonal 1.3 0.68-2.4 20/52 33/104
aControls matched to the cases which fall in the indicated leukaemia category. Note that the relative risks in
the table take account of the matching, and may differ somewhat from the relative risks calculable from the
summary numbers of treated cases and controls.
was 3.8 (90% CI: 1.4-10.5). For women aged 50-60 the
relative risk of acute leukaemia following any chemotherapy
was 1.2 (90% CI: 0.34-4.5).
Among ovarian tumour patients there was no indication
that the risk of developing leukaemia following chemo-
therapy was confined to women under 50. The estimate of
relative risk for women over 50 (7 cases) was 7.1, and was
infinite for those under 50 (5 cases).
Effect ofdose
Risk of developing leukaemia was examined by total dose of
cyclophosphamide recorded in the hospital chart (when
available). Table IV gives the number of cases and controls
in each dose category, and the associated (unmatched)
relative risk. Although the relative risks did not follow a
clear pattern with dose in either the ovarian tumour or
breast cancer group, there was a general trend to higher
relative risks with increasing dose when the estimates were
combined. The breast cancer controls treated with cyclo-
phosphamide received an average of 17.4g (range 0.4-235),
as compared with 62.4 g (0.9-275) for the ovarian cancer
controls.
Discussion
An excess risk of acute leukaemia occurred among both
ovarian tumour and breast cancer patients treated with
cyclophosphamide. These data provide evidence for the
leukaemogenicity of cyclophosphamide in humans since (i)
the increases in relative risk were both large and statistically
significant; (ii) cyclophosphamide was used as a single agent
in most patients who received cyclophosphamide during this
period; and (iii) there was no evidence of increased
leukaemia risk in relation to radiation or hormone treat-
ments. The excess could not be an observational bias due to
increased survival for those treated with cyclophosphamide,
since controls were matched on length of survival. If stage of
the first primary cancer was related to the risk of leukaemia,
a spurious relationship with cyclophosphamide therapy could
be induced. However, for ovarian and breast cancer, this
possibility seems unlikely.
In contrast to most studies of the association between
chemotherapy and second primary tumours, the present
study employed a case-control instead of a cohort design.
Patients with breast cancer or ovarian cancer who had
developed leukaemia were matched with other patients with
the same primary tumour who had not developed leukaemia,
and the treatments which had been received for their first
malignancies were compared. This method was appropriate
since leukaemia is rare as a second primary cancer: Only 12
cases following ovarian cancer and 93 after breast cancer
were identified for a 13-year period and a population base of
some 9 million women. It also provides an economical
framework for abstraction of treatment records. Although
the relative risk of leukaemia associated with cyclo-
phosphamide therapy can be estimated from this approach,
direct measures of risk, such as cumulative risk, cannot be
Table IV Relative riska (RR) of leukaemia associated with cyclophosphamide by total dose (based on information
in hospital chart and limited to patients for whom chart was available)
Ovarian tumours Breast cancer Combinedc
Leukaemia Leukaemia Leukaemia
Dose cases Controls RR cases Controls RR cases Controls RR
None 1 23 1.0 56 132 1.0 57 155 1.0
Any 9 13 15.9 13 19 1.7 20 32 2.4
< lOg 3 3 23.0 6 15 0.9 9 18 1.5
10-29g 3 3 23.0 0 2 0 3 5 3.3
30+ g 2 6 7.7 3 1 7.0 5 7 7.3
Unknownb 1 1 23.0 4 1 9.4 5 2 10.9
Chart
unavailable 2 12 24 35 26 47
Total 12 48 93 185 105 233
aRelative risk compared to those who received no cyclophosphamide; "Treatment with cyclophosphamide
specifically mentioned in the chart but no dose data recorded; cMantel-Haenszel method used to calculate summary
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calculated without relying on further information about the
study population. The annual incidence of acute leukaemia
among women in the GDR from Cancer Incidence in Five
Continents, Vol. IV (Waterhouse et al., 1982) is 4 per
100,000 in the age group 50-54. Taking the relative risk of
about 7 estimated from the highest dose group (Table IV)
would give an annual incidence of around 30 per 100,000 per
year acute leukaemias in cyclophosphamide-treated patients.
This corresponds to a 10-year cumulative incidence of 0.3%,
which is probably conservative, but substantially less than
the 10-year risk of ANLL following melphalan adjuvant
therapy for breast cancer (Fisher et al., 1985).
For ovarian cancer patients, the relative risk of leukaemia
following cyclophosphamide was increased over 14-fold.
Concern that a bias might be induced if the risk of
leukaemia were inherently different between patients with
non-malignant and malignant ovarian tumours led us to
repeat the analysis limiting it to malignant neoplasms only.
Since ovarian tumour patients with histologically malignant
disease are more likely to receive chemotherapy, this led to
an increase in the number of treated controls and decreased
the relative risk somewhat.
The magnitude of the leukaemia risk (2.7 for acute
leukaemia) in patients who received cyclophosphamide for
breast cancer was lower than that following ovarian
neoplasms. The risk, however, was entirely confined to
women who were less than 50 years old at the time of
treatment for breast cancer. For women under 50, the
magnitude (13.1) was comparable to that observed in
ovarian cancer patients. Why the excess risk is confined to
younger patients is unclear. It could not be explained by
differences in dose, although the mean dose received by all
breast cancer patients was less than one-third of that
received by the ovarian cancer patients. Among the ovarian
cancer patients with leukaemia, half were in the 50-59 year
age group, and three were over 60.
The magnitude of the observed relative risks certainly
makes confounding an unlikely explanation. Furthermore,
classification of the subjects with respect to whether they
ever received chemotherapy and by specific agent(s) is
probably accurate when the medical record was available.
Some patients, for whom medical records were unavailable,
may have been incorrectly classified as not having received
such treatment. However, since the proportion of cases and
controls with available hospital charts is similar, it is unlikely
that a bias was introduced in this way.
There is a strong suggestion of increasing risk with dose
when ovarian tumour and breast cancer patients are
combined. It is in fact possible that the incompleteness of
information on dose has somewhat diluted dose-response
relationships in the data. It was notable that the relative risk
for cyclophosphamide-treated patients with no dose
information in the chart was higher than that for any single
dose group. Since the treatment report on chemotherapy is
often submitted to the NCR at the start of the course of
treatment it may contain only the name of the agent(s)
administered and no information or incomplete information
on the total amount of drug given. Even if the hospital
record was available, dose information could also be absent
or incomplete when chemotherapy was administered in an
outpatient setting. This is especially likely for ovarian cancer
patients on long-term cyclophosphamide maintenance
therapy.
Radiotherapy was not associated with any excess risk of
leukaemia (nor of acute leukaemia) in this study. This is
consistent with previous findings in ovarian cancer patients
(Greene et al., 1982; Pedersen-Bjergaard et al., 1980) and
some other groups (Boice et al., 1983; Boivin & Hutchison,
1984). A small excess risk was seen in a large cohort of
women treated with radiotherapy for cervical cancer (Boice
et al., 1985).
The results of this study with regard to ovarian cancer are
perhaps to be expected, given the established carcinogenicity
of other related alkylating agents used in ovarian cancer
therapy. However, the risk of leukaemia following cyclo-
phosphamide treatment for breast cancer occurred at much
lower doses, and indicates that recent assurances about the
long-term safety of CMF adjuvant therapy for breast cancer
(National Institutes of Health, 1985) may require some
qualification.
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